SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 8.3% – Time to Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH) traded down 8.3% during trading on Wednesday . The company traded as low as $7.69 and last traded at $7.6670. 591,292 shares changed hands during mid-day trading, an increase of 128% from the average session volume of 259,581 shares. The stock had previously closed at $8.36.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Trading Down 8.3%

The business has a 50 day moving average of $6.89 and a two-hundred day moving average of $5.63. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market capitalization of $643.39 million, a price-to-earnings ratio of -6.69 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Equities analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insiders Place Their Bets

In other news, insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $8.91, for a total transaction of $89,100.00. Following the completion of the transaction, the insider directly owned 556,887 shares in the company, valued at $4,961,863.17. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy L. Hibbs sold 6,250 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total transaction of $54,250.00. Following the completion of the sale, the director owned 103,242 shares in the company, valued at $896,140.56. This represents a 5.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 336,342 shares of company stock worth $2,154,775 in the last quarter. Insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS in the 2nd quarter valued at $9,809,000. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Archon Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the period. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.